Zhongguancun announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received the “Notice of Acceptance” issued by the State Drug Administration, and the application for consistency evaluation of Buspirone hydrochloride tablets as generic drugs was accepted. Buspirone is the first non-benzodiazepine anxiolytic drug. Currently, 4 companies in China, including Beijing Huasu, have been approved for marketing generic drugs. Two of them have passed the consistent evaluation of the quality and efficacy of generic drugs.

Zhongguancun announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received the “Notice of Acceptance” issued by the State Drug Administration, and the application for consistency evaluation of Buspirone hydrochloride tablets as generic drugs was accepted. Buspirone is the first non-benzodiazepine anxiolytic drug. Currently, 4 companies in China, including Beijing Huasu, have been approved for marketing generic drugs. Two of them have passed the consistent evaluation of the quality and efficacy of generic drugs.